Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating mutations within the epidermal growth factor receptor (EGFR) frequently derive significant clinical and radiographic benefits from treatment with EGFR tyrosine kinase inhibitors (TKIs). As such, prospective identificat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Oncol
Auteurs principaux: Westover, D, Zugazagoitia, J, Cho, B C, Lovly, C M, Paz-Ares, L
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Reviews
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454547/
https://ncbi.nlm.nih.gov/pubmed/29462254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx703
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires